Q2 2026 saw 26% revenue growth, margin expansion, and a return to profitability, with strong clinician and visit growth. FY 2026 guidance was raised across revenue, margin, and EBITDA, reflecting continued operational momentum and disciplined capital deployment.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.